CJJD logo

China Jo-Jo Drugstores, Inc. (CJJD) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, China Jo-Jo Drugstores, Inc. (CJJD) es una empresa del sector Healthcare valorada en 0. Calificado con 42/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 42/100

China Jo-Jo Drugstores, Inc. (CJJD) Resumen de Asistencia Médica y Tuberías

CEOLei Liu
Empleados939
Sede CentralHangzhou, CN
Año de la oferta pública inicial (OPI)2009

China Jo-Jo Drugstores, Inc. retails and distributes pharmaceutical and healthcare products in China, operating through retail drugstores, online platforms, wholesale, and herb farming. With a focus on traditional Chinese medicine (TCM) and Western medicine, the company operates retail pharmacies and online stores, facing competition in China's evolving healthcare market.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

China Jo-Jo Drugstores, Inc. presents a unique investment proposition within the Chinese healthcare market, characterized by its integrated approach to retail pharmacy, online sales, wholesale distribution, and herb farming. With a market capitalization of $0.01 billion and a P/E ratio of 1.20, the company's valuation metrics suggest potential undervaluation relative to its earnings. The company's profit margin of 8.5% and gross margin of 3.2% indicate areas for improvement in operational efficiency and cost management. Key growth catalysts include expanding its online pharmacy presence to capitalize on the growing e-commerce trend in China, and leveraging its TCM herb farming operations to meet increasing demand for traditional medicine. However, investors may want to evaluate the potential risks associated with operating in a highly regulated market, including evolving healthcare policies and pricing pressures. The company's beta of -0.15 suggests a low correlation with the broader market, potentially offering downside protection during market downturns.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $0.01 billion, indicating a small-cap company with potential for growth.
  • P/E ratio of 1.20, suggesting the company may be undervalued compared to its earnings.
  • Profit margin of 8.5%, reflecting the company's profitability in the pharmaceutical retail sector.
  • Gross margin of 3.2%, indicating the percentage of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services it sells.
  • Operated 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 4 drugstores as of March 31, 2021, demonstrating a significant retail presence.

Competidores y Pares

Fortalezas

  • Established retail pharmacy network in China.
  • Integration of traditional Chinese medicine (TCM) with Western medicine.
  • Online pharmacy platform providing convenient access to healthcare products.
  • Herb farming operations ensuring a stable supply of TCM ingredients.

Debilidades

  • Relatively small market capitalization compared to larger competitors.
  • Gross margin of 3.2% indicates potential inefficiencies.
  • Limited geographic diversification outside of China.
  • Dependence on regulatory approvals for pharmaceutical products.

Catalizadores

  • Upcoming: Expansion of online pharmacy platform to increase market reach and sales.
  • Ongoing: Leveraging TCM expertise to develop new products and services for domestic and international markets.
  • Upcoming: Strategic partnerships with other healthcare providers or technology companies to enhance capabilities.
  • Ongoing: Efforts to improve operational efficiency and increase profit margins.

Riesgos

  • Potential: Intense competition from other pharmaceutical retailers and online pharmacies.
  • Ongoing: Evolving healthcare regulations and pricing pressures in China.
  • Potential: Product recalls or safety concerns related to pharmaceutical products.
  • Potential: Fluctuations in the cost of raw materials for TCM herbs.
  • Ongoing: Dependence on regulatory approvals for pharmaceutical products.

Oportunidades de crecimiento

  • Expansion of Online Pharmacy Platform: China Jo-Jo Drugstores can capitalize on the increasing e-commerce penetration in China by expanding its online pharmacy platform. The Chinese online pharmacy market is projected to reach $49.7 billion in 2026, presenting a significant growth opportunity. By enhancing its online platform with a wider range of products, improved user experience, and strategic partnerships with e-commerce giants, the company can attract a larger customer base and drive online sales growth. Timeline: Ongoing.
  • Leveraging Traditional Chinese Medicine (TCM): With the growing popularity of TCM in China and globally, China Jo-Jo Drugstores can leverage its herb farming operations to meet the increasing demand for TCM products. The global TCM market is expected to reach $200 billion by 2025. By expanding its herb cultivation and processing capabilities, the company can ensure a stable supply of high-quality TCM ingredients and develop new TCM-based products for both domestic and international markets. Timeline: Ongoing.
  • Strategic Partnerships and Acquisitions: China Jo-Jo Drugstores can pursue strategic partnerships and acquisitions to expand its market reach and product offerings. Collaborating with other healthcare providers, pharmaceutical manufacturers, or technology companies can create synergies and enhance the company's competitive position. Acquiring smaller pharmacy chains or healthcare-related businesses can accelerate its expansion into new geographic areas or product categories. Timeline: Upcoming.
  • Enhancing Retail Pharmacy Network: While already having a retail presence, China Jo-Jo Drugstores can optimize its existing network of retail pharmacies by improving store layouts, product assortment, and customer service. Implementing data analytics to understand customer preferences and optimize inventory management can enhance sales and profitability. Expanding the range of healthcare services offered at its pharmacies, such as health screenings and consultations, can also attract more customers. Timeline: Ongoing.
  • Expanding Drug Wholesale Business: China Jo-Jo Drugstores can increase its revenue by expanding its drug wholesale business. By establishing partnerships with more pharmaceutical manufacturers and distributors, the company can increase the volume of products it distributes. Focusing on niche or specialized pharmaceutical products can also provide a competitive advantage. Timeline: Ongoing.

Oportunidades

  • Expansion of online pharmacy platform to reach more customers.
  • Leveraging TCM expertise to develop new products and services.
  • Strategic partnerships and acquisitions to expand market reach.
  • Increasing demand for healthcare products and services in China.

Amenazas

  • Intense competition from other pharmaceutical retailers and online pharmacies.
  • Evolving healthcare regulations and pricing pressures in China.
  • Potential for product recalls or safety concerns.
  • Fluctuations in the cost of raw materials for TCM herbs.

Ventajas competitivas

  • Established retail pharmacy network in China.
  • Integration of traditional Chinese medicine (TCM) with Western medicine.
  • Online pharmacy platform providing convenient access to healthcare products.
  • Herb farming operations ensuring a stable supply of TCM ingredients.

Acerca de CJJD

Founded in 2003 and headquartered in Hangzhou, China, China Jo-Jo Drugstores, Inc. has evolved into a multifaceted healthcare company operating across various segments of the pharmaceutical industry. The company's primary business involves retailing and distributing pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices. These products are offered through its network of retail drugstores, operating under the Jiuzhou Grand Pharmacy name, and its online pharmacy platforms. The company also provides convenience products, such as consumable, seasonal, and promotional items. China Jo-Jo Drugstores distinguishes itself by integrating traditional and Western medical practices, offering on-site consultations with licensed doctors of Western medicine and TCM. This approach caters to a broad customer base seeking both conventional and alternative healthcare solutions. In addition to its retail operations, the company engages in drug wholesale, distributing third-party pharmaceutical products to trading companies. It also cultivates and wholesales herbs used for TCM, further diversifying its revenue streams. As of March 31, 2021, China Jo-Jo Drugstores operated 109 retail pharmacies under the Jiuzhou Grand Pharmacy name, along with 4 additional drugstores, demonstrating its established presence in the Chinese pharmaceutical retail market.

Qué hacen

  • Operates retail drugstores under the Jiuzhou Grand Pharmacy name.
  • Sells prescription and over-the-counter drugs.
  • Offers nutritional supplements and traditional Chinese medicines (TCM).
  • Provides personal and family care products and medical devices.
  • Operates an online drugstore retailing OTC drugs and nutritional supplements.
  • Sells products through third-party online platforms.
  • Distributes third-party pharmaceutical products to trading companies.
  • Cultivates and wholesales herbs used for TCM.

Modelo de Negocio

  • Retail sales of pharmaceutical products through physical stores.
  • Online sales of pharmaceutical products through its online pharmacy.
  • Wholesale distribution of pharmaceutical products to other companies.
  • Cultivation and sale of herbs used in traditional Chinese medicine.

Contexto de la Industria

China Jo-Jo Drugstores operates within the rapidly evolving Chinese healthcare market, which is characterized by increasing demand for pharmaceutical products and healthcare services. The market is driven by factors such as an aging population, rising disposable incomes, and growing awareness of health and wellness. The competitive landscape includes both domestic and international players, ranging from large pharmaceutical manufacturers to retail pharmacy chains. China Jo-Jo Drugstores differentiates itself through its integrated business model, combining retail pharmacy, online sales, wholesale distribution, and herb farming. The company's focus on traditional Chinese medicine (TCM) also provides a unique selling proposition in a market where TCM remains highly valued.

Clientes Clave

  • Individual consumers seeking prescription and over-the-counter medications.
  • Customers interested in nutritional supplements and personal care products.
  • Patients seeking traditional Chinese medicine (TCM) remedies.
  • Trading companies purchasing pharmaceutical products for distribution.
Confianza de la IA: 80% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de China Jo-Jo Drugstores, Inc. (CJJD): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CJJD.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para CJJD.

MoonshotScore

42/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de CJJD en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Lei Liu

CEO

Lei Liu is the Chief Executive Officer of China Jo-Jo Drugstores, Inc. His background encompasses extensive experience in the pharmaceutical retail sector in China. Details regarding his specific educational background and prior roles are not available. As CEO, he is responsible for overseeing the company's strategic direction, operational performance, and financial results. He manages a workforce of 939 employees.

Historial: Since becoming CEO, Lei Liu has focused on expanding the company's online presence and leveraging its traditional Chinese medicine (TCM) capabilities. Specific milestones and achievements under his leadership are not available, but the company continues to operate in a competitive market. He is responsible for navigating the evolving regulatory landscape and driving growth in the Chinese healthcare market.

Lo Que los Inversores Preguntan Sobre China Jo-Jo Drugstores, Inc. (CJJD)

¿Cuáles son los factores clave para evaluar CJJD?

China Jo-Jo Drugstores, Inc. (CJJD) actualmente tiene una puntuación IA de 42/100, indicando puntuación baja. Fortaleza clave: Established retail pharmacy network in China.. Riesgo principal a monitorear: Potential: Intense competition from other pharmaceutical retailers and online pharmacies.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de CJJD?

CJJD actualmente puntúa 42/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de CJJD?

Los precios de CJJD se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre CJJD?

La cobertura de analistas para CJJD incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en CJJD?

Las categorías de riesgo para CJJD incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from other pharmaceutical retailers and online pharmacies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de CJJD?

La relación P/E para CJJD compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está CJJD sobrevalorada o infravalorada?

Determinar si China Jo-Jo Drugstores, Inc. (CJJD) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de CJJD?

China Jo-Jo Drugstores, Inc. (CJJD) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information is based on available data and may be subject to change.
  • AI analysis is pending for CJJD, which may provide further insights.
  • The Chinese healthcare market is subject to regulatory and economic uncertainties.
Fuentes de datos

Popular Stocks